Covid: AstraZeneca vaccine 79% effective with no increased blood clot risk – US trial

Read Time:31 Second

Study of over 32,000 people included review of risks of cerebral venous sinus thrombosis

The Covid-19 vaccine developed by Oxford University and AstraZeneca was 79% effective in preventing symptomatic illness in a large trial in the US, Chile and Peru, the company said on Monday, paving the way for it to apply for US approval.

The vaccine was 100% effective against severe or critical disease and hospitalisation and was safe, the drugmaker said on Monday, releasing results of the late-stage human trial study of more than 32,000 volunteers across all age groups.

Continue reading… Source: The Guardian

0 0
Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleppy
Sleppy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %

Average Rating

5 Star
0%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Leave a Reply

Your email address will not be published.